gMG Connect
  • Saved

2yr
Real-World Experience With Efgartigimod in Patients With Myasthenia Gravis

Real-World Experience With Efgartigimod in Patients With Myasthenia Gravis

Source : https://pubmed.ncbi.nlm.nih.gov/38528163/

Recommendations for the treatment of myasthenia gravis (MG) have been difficult to develop because of limited evidence from large randomized controlled trials. New drugs and treatment approaches have recently been...

Twenty patients (86.3%) improved by ≥2 MG-ADL points after the first treatment cycle.

  • Saved

2yr
Patient Perceptions of Disease Burden and Treatment of Myasthenia Gravis Based on Sentiment Analysis of Digital Conversations

Patient Perceptions of Disease Burden and Treatment of Myasthenia Gravis Based on Sentiment Analysis of Digital Conversations

Source : https://www.nature.com/articles/s41598-024-57825-1

Myasthenia gravis (MG) is a rare, autoimmune, antibody-mediated, neuromuscular disease. This study analyzed digital conversations about MG to explore unprovoked perspectives. Advanced search, data extraction, and artificial intelligence-powered algorithms were...

Key differences were observed between men and women in terms of sentiments and mindsets toward MG that could have implications for disease management, and a high degree of negativity was noted among patients with MG who had been treated with steroids or intravenous immunoglobin therapies.

  • Saved

2yr
American Academy of Neurology Annual Meeting

The American Academy of Neurology (AAN) will hold its annual meeting in Denver and online from April 13 to 18, 2024. The meeting boasts more than 2,600 accepted abstracts covering 27 specialty areas, more than 180 courses, and the potential for more than 550 continuing medical education (CME) credits.

  • Saved

2yr
Rozanolixizumab: a New Therapy in the Treatment of Myasthenia Gravis

Rozanolixizumab: a New Therapy in the Treatment of Myasthenia Gravis

Source : https://pubmed.ncbi.nlm.nih.gov/38533739/

The approval of rozanolixizumab represents an advancement in therapy for generalized myasthenia gravis. The provision of individualized, targeted, and well-tolerated treatment is valuable for the patients whose myasthenia gravis is...

The approval of rozanolixizumab represents an advancement in therapy for generalized myasthenia gravis.

  • Saved

2yr
Case Report: Neurological Adverse Events in Subject With Myasthenia Gravis After PCSK9 Inhibitor Administration

Case Report: Neurological Adverse Events in Subject With Myasthenia Gravis After PCSK9 Inhibitor Administration

Source : https://pubmed.ncbi.nlm.nih.gov/38532873/

Based on the neurologist's conclusion, it can be assumed that in this case, treatment with PCSK9i resulted in significant worsening of the patient's chronic disease.

In this case, treatment with a PCSK9 inhibitor resulted in significant worsening of the patient's chronic disease.